| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
(R)-Prinomastat targets matrix metalloproteinases (MMPs), a family of zinc-dependent endopeptidases that degrade extracellular matrix (ECM) components. It inhibits MMP-2, MMP-9, MMP-13, MMP-14, MMP-1 (IC₅0 7.5 nM for MMP-14). It reduces invasion and metastasis, and inhibits angiogenesis by blocking VEGF release and endothelial cell migration.
|
|---|---|
| ln Vitro |
In vitro, (R)-Prinomastat (1-100 nM) inhibits tumor cell invasion through Matrigel in a dose-dependent manner. In HT1080 fibrosarcoma cells, it reduces type IV collagen degradation (IC₅0 5 nM). It inhibits HUVEC capillary tube formation (IC₅0 10 nM) and reduces VEGF-induced angiogenesis. It is cytostatic, not cytotoxic (IC₅0 >10 uM for viability).
|
| ln Vivo |
In vivo, (R)-Prinomastat demonstrated anti-tumor and anti-angiogenic activity in xenograft models. In a U87 glioblastoma orthotopic model, oral administration (50-200 mg/kg BID) reduces tumor size, extends survival, and reduces tumor angiogenesis. In combination with chemotherapy (carboplatin/paclitaxel) in NSCLC xenografts, it enhances activity. Phase 2 trials in glioblastoma and NSCLC showed no benefit; development discontinued.
|
| Enzyme Assay |
For MMP inhibition assays (fluorescence), recombinant MMPs are activated and incubated with (R)-prinomastat (0.001-10 uM) in assay buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10 mM CaCl2, 0.05% Brij-35). A fluorogenic MMP substrate (e.g., Mca-PLGL-Dpa-AR-NH2, 5-10 uM) is added, and fluorescence (Ex/Em 328/393 nm) is monitored. For invasion assays, Matrigel-coated Boyden chambers are used.
|
| Cell Assay |
For in vitro cell invasion, HT1080 cells are seeded in the upper chamber of a Matrigel-coated Transwell (8 um pores, 1 × 10⁵ cells/insert). (R)-Prinomastat (0.1-100 nM) is added to both chambers. After 24 h at 37degC, non-invading cells are removed, and invading cells are stained (crystal violet) and counted. For tube formation, HUVECs are seeded on Matrigel with VEGF (20 ng/mL). (R)-Prinomastat (1-100 nM) is added, and tube length is quantified.
|
| Animal Protocol |
For orthotopic glioblastoma model, female athymic nude mice are injected with U87 cells (5 × 10⁵) intracranially. (R)-Prinomastat (50-200 mg/kg BID) is administered orally. Survival is monitored. For NSCLC models, mice are xenografted with A549 or H460 cells and given (R)-prinomastat (50 mg/kg BID) orally.
|
| ADME/Pharmacokinetics |
(R)-Prinomastat is orally bioavailable (F~50%). Tmax 1-2 h; t1/2 3-5 h in rats. High plasma protein binding (>90%). Metabolized by CYP3A4; eliminated in feces.
|
| Toxicity/Toxicokinetics |
Clinical trials: Well tolerated; dose-limiting toxicity was arthralgia (joint pain) and myalgia, due to inhibition of MMPs involved in tissue remodeling. No significant hematological or hepatic toxicity. Preclinical: NOAEL >200 mg/kg.
|
| References | |
| Additional Infomation |
(R)-Prinomastat (AG3340) is an investigational MMP inhibitor discontinued in Phase 3. Not FDA-approved. Used as a research tool. For research use only.
|
| Molecular Formula |
C18H21N3O5S2
|
|---|---|
| Molecular Weight |
423.51
|
| Exact Mass |
423.092
|
| CAS # |
207795-16-2
|
| PubChem CID |
54513250
|
| Appearance |
Off-white to light yellow solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
638
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
N1(S(C2=CC=C(OC3C=CN=CC=3)C=C2)(=O)=O)CCSC(C)(C)[C@H]1C(NO)=O
|
| Synonyms |
(R)-AG3340; (R)-KB-R9896
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3612 mL | 11.8061 mL | 23.6122 mL | |
| 5 mM | 0.4722 mL | 2.3612 mL | 4.7224 mL | |
| 10 mM | 0.2361 mL | 1.1806 mL | 2.3612 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
